Hormone receptor (HR)-positive, human epidermal growth factor receptor 2(HER2)-negative early breast cancer accounts for nearly 70% of all breast cancers and generally has a favorable prognosis (Giaquinto et al., 2022). This evidence concerns the gene NR4A1 and breast carcinoma.